GlassScriptPhysician profile
Raphaele Espina Alaura
NPI 1821693037
$5,408.55
in general payments reported to CMS, 2019-2025
40 companies · $610 in 2025
The $610 reported for 2025 was more than what 77% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,075 · 2023: $1,397 · 2024: $2,326 · 2025: $610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,825 · Long Term Medical Supply Or Device Loan: $1,280 · Education: $229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,824.61 |
| Long Term Medical Supply Or Device Loan | $1,279.73 |
| Education | $228.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,960.57 | 2022-2025 | |
| Horizon Therapeutics Plc | $576.58 | 2022 | |
| Daiichi Sankyo INC. | $410.29 | 2022-2024 | Enhertu, Injectafer |
| Lilly USA, LLC | $329.35 | 2022 | |
| Celgene Corporation | $195.25 | 2022-2025 | Reblozyl, Pomalyst |
| Seagen INC. | $140.75 | 2023 | Padcev, Adcetris |
| Abbvie INC. | $139.23 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $119.26 | 2023-2024 | Keytruda, Welireg |
| Pfizer INC. | $105.68 | 2023-2024 | |
| Amgen INC. | $100.58 | 2023 | Nplate, Xgeva, Vectibix |
| Ipsen Biopharmaceuticals, INC | $92.08 | 2023-2024 | Onivyde, Somatuline Depot |
| Incyte Corporation | $91.66 | 2022-2023 | Monjuvi, Jakafi |
| Aveo Pharmaceuticals, INC. | $79.95 | 2024 | |
| Gilead Sciences, INC. | $74.99 | 2023 | Trodelvy |
| Exelixis INC. | $72.27 | 2023 | Cabometyx |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $71.31 | 2024 | Xospata, Xtandi, Padcev |
| Takeda Pharmaceuticals U.S.A., INC. | $69.85 | 2023-2024 | Alunbrig, Fruzaqla |
| Glaxosmithkline, LLC. | $68.41 | 2023-2024 | Zejula, Jemperli, Ojjaara |
| Astrazeneca Pharmaceuticals LP | $59.93 | 2023 | Imfinzi, Calquence |
| Array Biopharma INC | $59.53 | 2023-2024 | Mektovi, Lorbrena, Braftovi |
| Alexion Pharmaceuticals, INC. | $55.41 | 2024 | Ultomiris |
| Sumitomo Pharma America, INC. | $50.14 | 2024 | Orgovyx |
| Eisai INC. | $44.18 | 2023-2024 | |
| Sobi, INC | $40.33 | 2024 | |
| Genentech USA, INC. | $39.44 | 2023-2024 | Tecentriq, Polivy |
| Sun Pharmaceutical Industries INC. | $36.85 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $36.53 | 2023 | Libtayo |
| Stemline Therapeutics INC. | $36.12 | 2023-2024 | Orserdu |
| Karyopharm Therapeutics INC. | $32.50 | 2024 | Xpovio |
| Boston Scientific Corporation | $30.76 | 2023 | |
| Mirati Therapeutics, INC. | $25.15 | 2023 | Krazati |
| Genzyme Corporation | $24.09 | 2023 | |
| Irhythm Technologies, INC. | $20.32 | 2023 | Zio Xt Patch |
| Servier Pharmaceuticals LLC | $19.95 | 2023 | |
| Emd Serono, INC. | $18.45 | 2024 | |
| Kyowa Kirin, INC. | $18.34 | 2023 | Poteligeo |
| Dendreon Pharmaceuticals LLC | $17.39 | 2024 | Provenge |
| Octapharma USA, INC. | $15.11 | 2023 | Octagam Immune Globulin (Human) |
| Accord Healthcare, INC. | $15.09 | 2024 | |
| Janssen Biotech, INC. | $14.88 | 2023 | Darzalex, Tecvayli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raphaele Alaura listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.